A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Nirsevimab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Acronyms PK/ADA
- Sponsors AstraZeneca
Most Recent Events
- 07 Dec 2021 Status changed from active, no longer recruiting to completed.
- 13 Oct 2021 Planned End Date changed from 10 Dec 2021 to 19 Nov 2021.
- 13 Oct 2021 Planned primary completion date changed from 10 Dec 2021 to 19 Nov 2021.